N-(3,5-dichloro-pyridin-4-yl)-4-difluoromethoxy-8-nitro-dibenzo[b,d]furane-1-carboxamide | 685875-02-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: N-(3,5-dichloro-pyridin-4-yl)-4-difluoromethoxy-8-nitro-dibenzo[b,d]furane-1-carboxamide
• 英文别名: N'-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-nitro-dibenzo[b,d]furan-1-carboxamide；N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-nitro-dibenzo[b,d]furan-1-carboxamide；N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-nitrodibenzo[b,d]furan-1-carboxamide；N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-8-nitrodibenzofuran-1-carboxamide
• CAS: 685875-02-9
• 化学式: C₁₉H₉Cl₂F₂N₃O₅
• 分子量: 468.2
• InChiKey: JPTXIRPMPDVJTP-UHFFFAOYSA-N

物化性质

• 沸点：
  542.2±50.0 °C(Predicted)
• 密度：
  1.651±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  N-(3,5-dichloro-pyridin-4-yl)-4-difluoromethoxy-8-nitro-dibenzo[b,d]furane-1-carboxamide 在 钯 甲醇 作用下， 以 甲醇 为溶剂， 反应 12.0h， 以afforded N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-amino-dibenzo[b,d]furan-1-carboxamide as white solid的产率得到N1-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-amino-dibenzo[b,d]furan-1-carboxamide
  参考文献：
  名称：

  NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

  摘要：

  本发明涉及新型杂环化合物及其类似物、互变异构体、位置异构体、立体异构体、对映异构体、非对映异构体、多型体、药学上可接受的盐、适当的N-氧化物、药学上可接受的溶剂和包含它们的药物组合物。本发明更特别涉及式（1）的新型磷酸二酯酶4（PDE4）抑制剂及其类似物、互变异构体、对映异构体、非对映异构体、位置异构体、立体异构体、多型体、药学上可接受的盐、适当的N-氧化物、药学上可接受的溶剂和包含它们的药物组合物。

  公开号：

  US20070105854A1
• 作为产物：
  描述：

  4-difluoromethoxy-8-nitro-benzo[b,d]furane-1-carboxylic acid chloride 在 potassium tert-butylate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以74.28%的产率得到N-(3,5-dichloro-pyridin-4-yl)-4-difluoromethoxy-8-nitro-dibenzo[b,d]furane-1-carboxamide
  参考文献：
  名称：

  SYNTHESIS OF HETEROCYCLIC COMPOUNDS

  摘要：

  合成杂环化合物的方法，包括N-(3,5-二氯吡啶-4-基)-4-二氟甲氧基-8-甲磺酰氨基-二苯并[b,d]呋喃-1-羧酰胺及其药用盐。

  公开号：

  US20080009632A1

文献信息

• [EN] NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX COMPOSES TRICYCLIQUES UTILES POUR TRAITER LES TROUBLES INFLAMMATOIRES ET ALLERGIQUES, PROCEDE DE PREPARATION DE CES COMPOSES ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：GLENMARK PHARMACEUTICALS LTD

  公开号：WO2004037805A1

  公开（公告）日：2004-05-06

  The present invention relates to novel tricyclic compounds useful for the treatment of inflammatory conditions, diseases of the central nervous and insulin resistant diabetes.

  本发明涉及用于治疗炎症性疾病、中枢神经系统疾病和胰岛素抵抗性糖尿病的新型三环化合物。
• [EN] NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX COMPOSES HETEROCYCLIQUES POUR LE TRAITEMENT DES AFFECTIONS INFLAMMATOIRES ET ALLERGIQUES, LEUR PROCEDE DE PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：GLENMARK PHARMACEUTICALS LTD

  公开号：WO2004089940A1

  公开（公告）日：2004-10-21

  The present invention relates to novel heterocyclic compounds, their analogs, their tautomers, their regioisomers, their stereoisomers, their enantiomers, their diastereomers, their polymorphs, their pharmaceutically acceptable salts, their appropriate N-oxides, their pharmaceutically acceptable solvates and their pharmaceutical compositions containing them. The present invention more particularly relates to novel Phosphodiesterase type 4 (PDE4) inhibitors of the formula (1), their analogs, their tautomers, their enantiomers, their diasteromers, their regioisomers, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their appropriate N-oxide, their pharmaceutically acceptable solvates and the pharmaceutical compositions containing them. The groups X, Ar, Y, P and R1-R4 are defined in claim 1.

  本发明涉及新颖的杂环化合物，它们的类似物，其互变异构体，其位置异构体，其立体异构体，其对映异构体，其二对映异构体，其多晶形式，其药用可接受盐，其适当的N-氧化物，其药用可接受溶剂和含有它们的药物组合物。本发明更具体地涉及公式（1）的新型磷酸二酯酶4型（PDE4）抑制剂，其类似物，其互变异构体，其对映异构体，其二对映异构体，其位置异构体，其立体异构体，其多晶形式，其药用可接受盐，其适当的N-氧化物，其药用可接受溶剂和含有它们的药物组合物。其中，X、Ar、Y、P 和 R1-R4 组在权利要求书中有定义。
• Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
  申请人：Glenmark Pharmaceuticals, S.A.

  公开号：US07393846B2

  公开（公告）日：2008-07-01

  The present invention relates to novel heterocyclic compounds, their analogs, their tautomers, their regioisomers, their stereoisomers, their enantiomers, their diastereomers, their polymorphs, their pharmaceutically acceptable salts, their appropriate N-oxides, their pharmaceutically acceptable solvates and their pharmaceutical compositions containing them. The present invention more particularly relates to novel Phosphodiesterase type 4 (PDE4) inhibitors of the Formula (1), their analogs, tautomers, enantiomers, diasteromers, regioisomers, stereoisomers, polymorphs, pharmaceutically acceptable salts, appropriate N-oxide, pharmaceutically acceptable solvates and the pharmaceutical compositions containing them.

  本发明涉及新型杂环化合物及其类似物、互变异构体、位置异构体、立体异构体、对映异构体、二对映异构体、多晶型、药学上可接受的盐、适当的N-氧化物、药学上可接受的溶剂化物和含有它们的制药组合物。本发明更具体地涉及公式（1）的新型磷酸二酯酶4（PDE4）抑制剂及其类似物、互变异构体、对映异构体、二对映异构体、位置异构体、立体异构体、多晶型、药学上可接受的盐、适当的N-氧化物、药学上可接受的溶剂化物和含有它们的制药组合物。
• Novel piperidine compound
  申请人：Takahashi Masami

  公开号：US20050239829A1

  公开（公告）日：2005-10-27

  The present invention provides a novel piperidine compound of the formula [I]: wherein Ring A represents an optionally substituted benzene ring, Ring B represents an optionally substituted benzene ring, R 1 represents an optionally substituted alkyl group, an optionally substituted hydroxyl group, etc., or a group of the formula: (a) wherein R 11 and R 12 are the same or different, and each represents hydrogen atom, a substituted carbonyl group, a substituted sulfonyl group, an optionally substituted alkyl group, etc., R 2 represents hydrogen atom, etc., Z represents oxygen atom or a group represented by —N(R 3 )—, R 3 represents hydrogen atom or an alkyl group, etc., R 4 represents hydrogen atom or an alkyl group, etc., or a pharmaceutically acceptable salt thereof.

  本发明提供了一种新型哌啶化合物，其化学式为[I]：其中，环A代表可选取代的苯环，环B代表可选取代的苯环，R1代表可选取代的烷基，可选取代的羟基等，或者是化学式为(a)的基团，其中R11和R12相同或不同，每个代表氢原子，取代的羰基基团，取代的磺酰基基团，可选取代的烷基等，R2代表氢原子等，Z代表氧原子或者由—N(R3)—表示的基团，R3代表氢原子或者烷基等，R4代表氢原子或者烷基等，或其药学上可接受的盐。
• Process for the preparation n-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methane sulfonamido-dibenzo[b,d]furan-1-carboxamide
  申请人：Gopalan Balasubramanian

  公开号：US20060135779A1

  公开（公告）日：2006-06-22

  The present invention relates to a method of preparing N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide and pharmaceutically acceptable salts thereof, such as its sodium salt, and novel intermediate compounds useful in the synthesis of the aforementioned compound.

  本发明涉及一种制备N-（3,5-二氯吡啶-4-基）-4-二氟甲氧基-8-甲磺酰氨基-二苯并[b,d]呋喃-1-羧酰胺及其药学上可接受的盐，例如其钠盐，以及在合成上述化合物中有用的新型中间体化合物的方法。